Loading...
XASX
MSB
Market cap2.27bUSD
Dec 05, Last price  
2.66AUD
1D
4.72%
1Q
25.47%
Jan 2017
87.90%
IPO
278.45%
Name

Mesoblast Ltd

Chart & Performance

D1W1MN
XASX:MSB chart
P/E
—
P/S
131.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
82.92%
Rev. gr., 5y
-11.76%
Revenues
17m
+191.39%
2,821,7581,679,317909,807890,7085,500120,921,28538,279,90228,786,00025,980,00023,748,00042,548,0002,412,00017,341,00016,722,00032,156,0007,456,00010,211,0007,501,0005,902,00017,198,000
Net income
-102m
L+16.13%
-8,298,587-8,728,131-10,062,379-12,285,459-14,780,89590,606,590-71,145,314-61,663,000-80,958,000-119,368,000-4,127,000-76,815,000-35,290,000-89,799,000-77,940,000-98,811,000-91,347,000-81,889,000-87,956,000-102,142,000
CFO
-50m
L+3.09%
-3,183,863-9,102,676-6,202,589-9,237,576-9,657,662108,228,873-72,116,783-54,081,000-81,861,000-121,709,000-87,996,000-95,471,000-75,012,000-57,790,000-56,365,000-106,681,000-65,782,000-63,269,000-48,458,000-49,954,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
URL
https://www.mesoblast.com/
IPO date
Dec 16, 2004
Employees
77
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT